Genetic Studies of Early-onset Dementia

ConditionsDementia, Early Onset Alzheimer Dementia (AD)Mild Cognitive Impairment (MCI)Memory Loss

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age35+

SponsorColumbia University

About this trial

The aim of this study is to identify genetic factors that contribute to risk and progression of early-onset dementia (loss of memory function before the age of 70 years) across all ethnic groups, including Alzheimer's Disease, mild cognitive impairment and other dementias.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

35 years and older

Individuals experiencing memory concerns or diagnosed with dementia and their family members that are unrelated healthy controls without dementia.

Disqualifiers

None

Trial population

The study population consists of individuals affected by dementia, mild cognitive impairment, cognitively healthy individuals with a family history of dementia. Ascertainment is across both males and females, and all race-ethnic groups.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Blood draw
Genetic
Blood draw for identification of genetic variants associated with the development of memory problems
Neurocognitive testing
Other intervention
Brief memory test
Medical questionnaire
Other intervention
Collection of medical history

Treatment groups

1,000 Participants

are divided into 4 treatment groups

Group A: Mild Cognitive Impairment3 interventions

Group B: Dementia/Alzheimer's Disease3 interventions

Group C: Cognitively Healthy3 interventions

Group D: Early-onset dementia prior to the age of 65.3 interventions

Trial outcomes

Primary outcomes

Genetic risk variants associated with early-onset dementia

Genetic factors will be measured through genome-wide genotyping arrays and/or whole-genome sequencing, and then correlated with Alzheimer disease and related phenotypes, such as cognitive impairment, functional impairment, and relevant biomarkers.

Time frame

2 years

Changes in blood biomarkers in early-onset dementia

Blood biomarkers including plasma amyloid beta and tau protein will be assessed in blood and correlated with onset and progression of memory loss and functional impairment

Time frame

2 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Columbia University

Lead sponsor

University of Miami

Collaborator

National Institute on Aging (NIA)

Collaborator

Source ClinicalTrials.gov

Apply now